Altair
Skip to content

Trading Analysis Report: INTC

Analysis date: 2026-10-14 · Model: claude-opus-5-5 · AI-generated, not financial advice.

  • Analysis date: 2026-10-14
  • Rating: Underweight
  • Generated: 2026-10-14 17:08:17
  • TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
  • Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
  • Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

V. Portfolio Manager Decision

Rating: Underweight

Executive Summary: Reduce INTC to about 40% of a standard allocation (a target weight, not a percentage of the portfolio), or to 25% if the Q2 10-Q shows a large cash-settled obligation, and open no new positions at 98.12. Work the first step through tomorrow's session: down to about 60% of standard on a clean filing read, or about 50% on an ambiguous or unresolved one. Finish the trim at the first of three triggers: resting orders at 101-104.70, a daily close below 94.52, or a time-stop at the Oct 21 close if the Q3 date is still unconfirmed by tomorrow's open (otherwise the session before the print). A daily close below 84.00 cuts the position to 25%, a close below 81.79 exits to zero, and a Fed hike or a Q3 miss cuts to 25%. The horizon runs through the Q3 print and the Oct 27-29 FOMC, roughly 1-3 months.

Current Price: 98.12

Price Target: 88.0

Confidence: Medium

Time Horizon: 1-3 months

IV. Risk Management Team Decision

Aggressive Analyst

Aggressive Analyst: Neither of you has spoken yet, so I'll open and take your likely objections head-on.

People hear "aggressive" and assume "long." It really means taking the side with the better asymmetry and acting on it decisively. INTC has gone from 35.63 to 98.12 in a year, with a beta of 2.23. It has also just shown us its tails: 140.94 on June 22 to 81.88 on July 29, a 42% drop in about five weeks. Then it rallied 56% to 127.39 and has since fallen 23% in 14 sessions. When the plan says to size the residual so a 25-40% gap is acceptable, that's just the last four months of tape. Standing pat at full weight through PPI tomorrow, Warsh at midday, and a late-October FOMC with hike odds at 30% after a 15-point weekly jump, then a Q3 print with no confirmed date, is the passive choice dressed up as conviction.

To the conservative: you'll say the evidence is bearish enough to exit entirely. The weekly SuperTrend is down, the MACD histogram has deepened for more than a week, and OBV is down 21.6%. At the same price as September 14, RSI is 38 versus 50 then. I agree with all of that, which is why we're cutting. But going to zero here means selling at the lower Bollinger band, with a daily z-score of -1.91 and a TD count of 7, on a bar that may not even be final. Today's volume has full-digit precision, which suggests the data was pulled mid-session. You'd also be walking away from a real operating story:

  • Revenue was up 25.4% year over year to $16.1B.
  • Gross margin has risen three straight quarters to 40.4%.
  • Operating income turned positive at $1.8B.
  • Q2 operating cash flow minus capex was about +$4.45B.
  • The CEO put roughly $10M in at $95.

The plan's answer is a staged exit. If you hold a standard allocation, sell about a quarter of it now and the rest of the trim into a bounce toward 101-104.70. A half-weight seat stays for the upside, and the 94.52, 84 and 81.79 triggers take us lower if the tape demands it.

I'll concede one thing you may raise. 94.52 is under one ATR from here, and ATR is 5.65. On a full position, that stop would be noise bait. But it's a daily-close trigger to accelerate a trim on a position we already want smaller, not a stop on the whole thesis. Getting hit costs a few points of timing on a portion.

To the neutral: your case is that the long-term structure is intact, with the monthly SuperTrend up and price 14% above the 200 SMA, and that fundamentals are turning, so hold. The monthly signal flips only on a close below 74.34, about 24% under here. A signal that tells you the trend broke after you've lost a quarter of the position isn't risk management. The weekly SuperTrend, which the technical report treats as primary, is already down, with its stop 27% overhead. The nearest meaningful resistance, the 50 SMA at 103.49, is 5.5% up. The daily SuperTrend flip is 18.7% away. The 200 SMA is 14% below, with event risk stacked in between. That setup isn't neutral.

On "the operating improvement is real," yes, and that's why this is a trim and not an exit. But look at what 46.9x forward EPS rests on. TTM EPS is -$2.12, and we don't know whether the $2.09 forward figure is GAAP or adjusted. A $12.8B gap sits between Q2 operating income and net income, and nothing in the data explains it. Equity fell $23.9B against an $11B loss, current liabilities jumped $8.8B, and weighted shares are up about 17% year over year. Each of those may have a benign explanation, but "maybe benign" on a $518.7B market cap at 9x sales isn't something I want at full weight. Missing information argues for smaller size, not for waiting. The plan already pre-commits a branch: if the 10-Q shows a recurring cash charge, go to 0-25%.

Both of you may also lean on sentiment, with retail saying "5% again?" and "we will never see 100 again," so contrarian buy. The labeled StockTwits tags are 67% bullish, but that's 8 of 12 labels in a 30-message window from one 90-minute stretch, and at least three of the eight bullish tags have no Intel thesis. Real capitulation usually arrives with a volume spike, and today's 102.9M is roughly the 20-day average. The language is capitulating, but the tape isn't.

Notice also how the market is treating good news. ASML printed strong earnings and chips sold off anyway. Intel's 350-watt inference GPU reached customer testing and the stock still fell 2.7%. When good news gets sold, you don't want full size going into the next cluster of binary events.

Where could I be wrong? A soft PPI and a strong TSMC print could squeeze this toward 107-116 quickly, given the stretched daily readings. The plan is built for that. Half the position stays, and we sell the rest into strength, not at the low. I'd rather give up part of a squeeze than carry full weight through a 30% chance of a hike. One caveat: the rate odds come from prediction markets and headlines because the FRED data failed, so the macro read is softer than I'd like.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Before I answer either of you point by point, I think we've converged more than the tone suggests. All three of us want less than full weight and all three want to keep a seat. The neutral's arithmetic, which I checked, says the whole fight over pace is worth about 1 to 1.5% of a standard allocation. The residual and the unanswered balance-sheet questions are worth five to ten times that. So I'll concede what you've earned and then defend what matters.

Concessions. - The bar is probably final. Posts running past 21:00Z are quoting 98.12, so I'm dropping that argument. My case doesn't need it. - The 10-Q is homework, not a calendar item. I framed it as a later branch, and that was wrong. The Q2 filing is out, so someone should read the three oddities before the weekend: the $12.8B below-the-line item, the $12.9B equity decline beyond the loss, and the $8.8B jump in current liabilities. - A time-stop beats a hard dependency on a bounce. I'll take it, set at October 23 or the session before the Q3 print once someone looks up the date, whichever is earlier. - The plan needs a re-add rule, since the weekly SuperTrend flips at 135.20 and is no use for that. - I need to correct myself on gross margin. I said it rose three straight quarters, and the neutral repeated it. With derived Q4 FY25 at about 36.2%, it's two sequential gains, 36.2 to 39.4 to 40.4. - The conservative is right that Q2 operating cash flow of $7.0B arrived alongside an $8.8B jump in current liabilities. I won't lean on the +$4.45B until the filing says how much was payables timing.

To the conservative. - You say I'm betting on a bounce to 103.49 or 107. The band starts at 101. Today's high was 101.34, and yesterday's close was 102.81. A limit at 101 is about half an ATR away. - "Good news gets sold" argues against carrying full weight into the print. It doesn't argue against a resting order half an ATR above the market. That order needs noise, not good news, and this stock produces 5.8% of it every day. - Your claim that the ladder sells more as it falls, so sell now, proves too much. If a close below 94.52 is the base case and the stock walks to 84, the same logic says you should be at 25% already. Your plan stops at 50% now and 25-35% later for reasons that logic doesn't explain. My ladder is priced against both outcomes. On a bounce, we sell higher. On a break, we sell at most about 4.5% worse on a quarter of the position. - You're fair about slippage on daily-close triggers, but it lands on that quarter slice, about a point of allocation, not on the half we're holding. - You said two of the last four quarters had operating losses around $3B. It's one. Q1 FY26 was -3.1B, and Q2 FY25 is five quarters back. The last four are +0.7, +0.6, -3.1 and +1.8, which is how TTM nets to -$77M. I'll grant that back-to-back large charges, in operating expense in Q1 and below the line in Q2, are why this is a trim and not a hold. - Your 10-14% cap fits "a mandate built around stability," but we were never told the mandate. My rule is that the residual should be the size at which a 40% drop on it is a loss you'd accept. A stricter mandate shrinks it automatically. - Committing now to 25-35% before Q3 "whether or not" the filing is clean throws away the information you asked for. This stock has shown both tails. It rose 56% off the July low and 39% in three weeks in September. You're designing around the left tail while the right tail is the same size.

To the neutral. - Your plan is mine with a third up front instead of a quarter. I'll take the third and work it through the session, so neither the 8:30 PPI nor Warsh at midday picks the price. - Your point that touching both 94.52 and 103.49 is near even odds supports resting orders on both sides. - You'd size the residual so a move to 74.34, about 24%, is tolerable, instead of 40%. That's a looser standard than the plan's, because a smaller assumed loss lets you hold more. The last leg was 42%, and the monthly stop is a trend signal, not a floor. I'd keep the tougher standard. - Your remeasurement idea is plausible but unverified. If the Q2 charge was share-price-linked, Q3 could look very different in either direction. That's one more reason to keep the seat and let the filing set its size. - I agree a clean 10-Q doesn't restore full weight at 46.9x forward EPS. That's why the plan caps the good branch at about half.

Where we still differ. The residual rides the print. The half seat is the bet and the trim is the hedge. If Q3 misses, the lower bands take over after the gap, and that's the price of owning a beta-2.23 name. I accept that on a half seat. The stock also enters the print 23% below where it was three weeks ago. That isn't cheap at 46.9x, but the bar is lower than at 127. A soft PPI and a good TSMC print could squeeze it toward 107-116, and we'd sell the rest into strength.

The plan, as amended. - Before the weekend: read the Q2 10-Q on those three items, confirm the Q3 date, and confirm whether the $2.09 forward EPS is GAAP. - Tomorrow: sell about a third of a standard allocation, worked through the session. - Next tranche: sell roughly another 15% on resting orders at 101-104.70, finishing at the time-stop. - Break trigger: a daily close below 94.52 finishes the trim at the next open. - Residual: about half, held only if the filing shows nothing recurring. A recurring cash charge, a Q3 miss or a hike takes it to the lower bands, and closes below 84 and 81.79 exit. - Re-add: nothing above half until Q3 confirms positive operating income and gross margin near 40%, and price is back above 103.49.

The macro read is softer than I'd like, because the FRED data failed and the rate odds come from prediction markets.

FINAL TRANSACTION PROPOSAL: SELL Aggressive Analyst: Before I get to the disagreements, I'll give up what I should. Neutral is right that I overreached on "the bar is lower than at 127." The number Intel has to hit is the same $2.09, and the stock is just 23% cheaper for it, going from about 61x to about 47x. That's a better price, not a lower bar, and I'll drop the wording. He's also right that my "size for a 40% drop" test mixed up two risks. The ladder handles slides and sizing handles gaps, so the right test is a 25% overnight gap on the residual, about twelve points of allocation at half weight and about nine at 37.5%. And Conservative is right that daily-close triggers don't protect against gaps, which is why sizing matters more than the ladder.

Conservative, start with your case for selling more tomorrow, which rests on carrying size through PPI and Warsh. If PPI is at 8:30, it's in the price at the open, before any order of ours fills unless we're trading premarket. Selling half instead of a third tomorrow doesn't hedge PPI at all. It hedges Warsh and what follows, on about a sixth of a standard allocation, and at a 5% move either way that's under one point. That's the pace argument we already agreed was small.

On the balance sheet, you set $35.7B of current liabilities against $12.9B of cash, but current assets are $57.2B, the current ratio is 1.60, and short-term investments aren't in the data. Cash alone is the wrong comparison. I can't tell from the data whether the liability jump is something owed or something already paid, since Q2 also had $7.0B of operating cash flow and a $7.3B financing outflow. That's the reason to read the filing tonight, and it isn't an argument for a deeper cut before reading it. You conceded that pre-committing throws away the information, then rebuilt the pre-commitment with a 35-40% ceiling on a clean read and 25% on a bad one. Ten to fifteen points of difference doesn't let the filing decide much.

You also call the smaller number the safer default. Neutral's arithmetic says the residual dispute is worth about two to three points of allocation in each direction, so a default that costs that much in a squeeze is no safer than one that costs it in a break. It's only safer if you assume the break. On gaps, the largest one the technical report names went up, 24% in April, and the stock also gained 39% in three weeks in September. The 42% drop took five weeks, and the ladder would have cut it along the way. I'm not saying a down-gap can't happen. But "gaps beat the ladder" describes a tail we haven't seen in this file, while the right tail has shown up twice. On the hike, any trigger on a binary event sells after the reaction. The alternative is pre-selling for a 30% event, which costs you in the 68% case. The stock also fell 23% over the same stretch that hike odds jumped 15 points, so some of that premium is already paid.

Neutral, I'm taking your matrix: a third if the filing is explained and non-recurring, half if ambiguous, a quarter or less if it shows a recurring cash charge, with residuals of about 45-50, 35-40 and 25 or less. I'd add two guardrails. If we can't find the answer tonight, that counts as ambiguous, not clean. And the residual should come from a stated rule, not a gut call. Take the loss the book can absorb on a 25% overnight gap and divide by 25%. If twelve points is tolerable, hold half. If it isn't, hold less. We don't know the mandate, so the plan should show the formula and let the holder plug in. Your point that the CEO bought at $95 after the Q2 filing was public is modest support at best. It suggests the filing is about recurrence, not surprise, but he knows the business better than we do and a purchase isn't a floor.

Here's why I'm still defending a half seat. The trim is the hedge and the residual is the bet, and the bet is a real one. Revenue is up 25% year over year, gross margin is near 40%, and operating income just turned positive. If Q3 confirms that, a stock at 47x that has already been cut by a quarter has room to be re-rated, and a smaller seat captures less of it. Everyone's re-add rule needs positive Q3 operating income and a price back above 103.49, so a deeper cut now also means rebuying higher after a squeeze.

The plan: tonight, read the three balance-sheet items, find the Q3 date, check whether $2.09 is GAAP, and pin down the FOMC day. Tomorrow, let the filing set the first sale and work it through the session. Then use resting orders at 101 to 104.70, a close under 94.52, or October 23 (the Friday before the 26th), or the session before the print if it comes earlier. Closes below 84 and 81.79 exit. Re-add only after Q3 confirms and price is back above 103.49.

FINAL TRANSACTION PROPOSAL: SELL (partial trim sized by the filing, keeping a seat for the Q3 print) Aggressive Analyst: Two of my arguments are gone. The hike premium isn't proven paid just because the stock fell 23% while the odds rose 15 points. A seven-session sector wipeout and a one-week odds move run on different clocks, so the drop shows sensitivity, not exhaustion. I also counted the right tail twice, and those 56% and 39% rallies were drifts. Drifts are what resting orders and a re-add rule are for, not a reason to carry extra size through an overnight event. I'll stop leaning on the CEO's $10M too. It says the Q2 filing wasn't a surprise to him two months ago, and nothing more.

Conservative, your best question was what the edge is in the residual. I don't have an informational edge on the print, and nobody in this file does. But as Neutral said, that cuts both ways. If the hold case and the Q3-confirms case are fairly priced, the trim has no edge either, and what's left is a risk budget. We already agreed on the formula: the loss the book can absorb on a 25% overnight gap, divided by 25%. A 45% seat swings about eleven points of allocation on a 24% gap, and the one big gap in the file, April's 66.78 to 82.54, was 23.6% up. The size of the move is a wash. Which direction is likelier is something the file can't tell us, with ADX at 15.7, the weekly z-score at -0.60 and the daily at -1.91 with a TD 7. Defaulting to the low end quietly assumes the break is likelier. I'd go with Neutral's middle band, because a standard allocation was already someone's decision to carry this beta.

On liquidity, I'll grant your number. Working capital fell from about $35.3B to $21.5B. But current assets fell only $4.9B, and Neutral showed that the cash side reconciles: 7.0 minus 3.8 minus 7.3 is about -4.1, against a reported -4.4. So the cash left through ordinary channels, and the $8.8B liability jump is the non-cash piece. The key question for tonight is whether that liability comes due in cash within twelve months. If it's a redemption or put obligation, that's the recurring-cash branch and I'd go to a quarter without argument. If it's a reclassification, a 1.60 current ratio isn't a liquidity problem. One pointer for tonight, unverified: the equity decline beyond the loss, about $12.8B, is nearly the same size as the below-the-line item, also about $12.8B. Two same-sized entries in one quarter look mechanically linked, which fits Neutral's single-event idea and tells you which note to open first.

Neutral, I take your split on "clean." Grade by cash versus non-cash and by mechanism, ignore management's word "non-recurring," and treat GAAP versus adjusted EPS as a valuation question that the 45 cap already prices. Conservative's swing numbers support this. Net income was $3.4B above operating income in Q3 FY25 and $12.8B below it in Q2 FY26, so GAAP EPS in this name can move by more than the operating story. That's a reason to size the seat from the gap budget and not from the $2.09.

One place I still differ is the way back in. Every version says nothing above half until Q3 confirms and price is back over 103.49. But the weekly SuperTrend doesn't flip until 135.20, so the 50 SMA reclaim is the only door, and it makes us rebuy higher. Suppose Q3 shows positive operating income and gross margin near 40%, and the Fed has the stock at 90 anyway. The same $2.09 is then a cheaper multiple than today's, and the rule says do nothing. I'd allow a first re-add of about a quarter of what we sold on a confirmed print once the FOMC is behind us, as long as price is above the 200 SMA at 84, and keep 103.49 as the condition for the rest. That makes the trim a risk reduction and not a permanent exit.

So here is the plan.

Tonight: read the three balance-sheet items and the working-capital split in Q2 operating cash flow. Find the Q3 date, check whether $2.09 is GAAP, and pin down the FOMC day.

Tomorrow: - Sell about a third of a standard allocation if the filing is clean. - Sell half if it's ambiguous or you couldn't resolve it tonight. - Go toward a quarter if it shows a recurring cash charge. - Work the sale through the session so neither PPI nor Warsh sets the price.

Second step: - Use resting orders at 101 to 104.70, a daily close below 94.52, or October 23 (or the close before the print if it comes earlier), whichever is first. - That lands the residual near 45%, 40% or 25%.

Exits and re-add: - Closes below 84 and 81.79 exit. - Re-add as above.

The seat is the bet, the trim is the hedge, and the filing decides how big each is.

FINAL TRANSACTION PROPOSAL: SELL (partial trim sized by the filing and a 25% gap budget, keeping a seat for the Q3 print) Aggressive Analyst: Most of what's left is you two being right, so I'll bank that first.

Conservative, you're right about the re-add. A rule that buys at 84.01 and exits at 83.99 only pays the spread, and with ATR near 6.7% of price at that level an ordinary day crosses the line. I'm dropping the 84 gate and taking Neutral's version. After a confirmed Q3 print with the FOMC behind us, we step back in on a close above 94.52, up to half. Anything beyond half needs the 103.49 reclaim. That keeps the way back in on the right side of our own break signal, which was the principle I cared about.

I also accept the grading test. Whether anything settles in cash, and how big it is against a year or two of free cash flow, is a better question than current versus noncurrent. Conservative's stake-purchase scenario is exactly the case where I'd go to a quarter without a fight. If the $7.3B of financing was a first payment and the $8.8B liability is the second, the Q2 operating story is carrying a bill the free cash flow line doesn't show. I can't tell that from here, but the filing can. The payables rule also stands. If working capital carried most of the $7.0B, a clean read drops a notch.

Neutral's point about proceeds deserves more weight than it got. If the money from the sale goes into AMD, NVDA or another high-beta chip name, we've bought back the same rate and AI-funding risk we just paid to cut. If the book holds other AI-linked names, the 25% gap test belongs on the whole pile, not on INTC alone. The date fallback is right too: unresolved gets the earlier date, the same way an unresolved filing gets the middle band. If we can't confirm the print by tomorrow's open, assume Thursday the 22nd and finish the second step at Wednesday's close.

I have three additions.

First, prioritize tonight's homework, because the items aren't equal. The cash-settlement question and the payables split can move the residual by fifteen to twenty points. The Q3 date moves the time-stop by a day or two. The GAAP-versus-adjusted question moves the clean branch by five points, and the $2.09 is a forward figure from the data provider, so the 10-Q can't tell you its basis. I'd cap that at ten minutes, and if it's unanswered the clean branch is 40, not 45. The FOMC day isn't on the critical path, since every version of it falls after the time-stop.

Second, a pointer for the filing, unverified. The equity decline beyond the net loss works out to about $12,819M from the table, and the gap between operating income and net income is $12,829M. A match within ten million dollars looks mechanical, so I'd look first for one item that shows up in both places. If the mark is tied to the share price, the stock was near its highs when Q2 closed on June 27 and its September high was about 127. The same mark could run the other way in Q3 and flatter GAAP. That's a hypothesis, not a finding. But it's one more reason not to make GAAP EPS a gate in either direction.

Third, our own matrix has a flaw. On a clean read we sell a third tomorrow and then another twenty-odd points at the second step to get to 45. So the part of the plan that rides on resting orders and the time-stop is biggest in the branch where we're most comfortable. That's the one place Conservative's pace worry still bites. It's cheap to fix, so I'll take it: on a clean read, sell closer to forty tomorrow, and the second step becomes mostly cleanup. It costs me almost nothing, and I'd rather give that up than lean on a bounce I've said I won't depend on.

What I'm still defending is the seat. Nobody in this file has an edge on the print, so the residual is a risk-budget decision, not a forecast. Forty to forty-five percent, sized from a 25% gap, is a budget a holder can survive in either direction. The trim is real and the exits are pre-committed. A recurring cash charge, a hike or a Q3 miss takes us to a quarter. A close below 94.52 finishes the trim, and closes below 84 and 81.79 exit.

That is what aggressive should mean here. We don't need the biggest position. We need the position whose downside is already paid for, so that if Q3 confirms 40% gross margin and cash-backed operating income, we're still in the stock at 47x with room for a re-rating. The remaining gap between your numbers and mine is a point or two of allocation. The evening with the 10-Q matters far more than the argument we're still having.

FINAL TRANSACTION PROPOSAL: SELL (partial trim sized by the filing and a 25% gap budget, residual 40% by default, time-stop at the earliest plausible Q3 date, not a full exit)